G
G

GSK

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Gsk PLC Reports 10.95% Passive Stake In Wave Life Sciences Ltd

BRIEF-Gsk PLC Reports 10.95% Passive Stake In Wave Life Sciences Ltd Jan 30 (Reuters) - GSK plc GSK.L : GSK PLC REPORTS 10.95% PASSIVE STAKE IN WAVE LIFE SCIENCES LTD. AS OF JANUARY 23, 2023 - SEC FILING Further company coverage: GSK.L
G

Unilever’s new boss whets appetite for split

BREAKINGVIEWS-Unilever’s new boss whets appetite for split The author is a Reuters Breakingviews columnist. The opinions expressed are their own. Refiles to fix typo in paragraph one. LONDON, Jan 30 (Reuters Breakingviews) - Unilever’s ULVR.L new chief executive is arguably a bit low fat. Had the $126 billion maker of Dove shampoo and Knorr stock cubes poached a big hitter from a major rival like Procter & Gamble PG.N to replace Alan Jope, it might have flagged confidence that the conglomera
G
H
R

Unilever names former Heinz exec Schumacher as CEO

UPDATE 6-Unilever names former Heinz exec Schumacher as CEO To become CEO July 1 Activist shareholder says met Schumacher when at Heinz First outsider CEO since Paul Polman appointed in 2008 Unilever shares outpace FTSE 100 Adds comment from businessman Leighton, graphic, updates shares By Richa Naidu LONDON, Jan 30 (Reuters) - Unilever ULVR.L on Monday appointed Hein Schumacher to replace Alan Jope as chief executive from July in a move that was welcomed by investors including board member and
G
N
A
K
R
U

Moderna data puts the spotlight on RSV vaccines under development

FACTBOX-Moderna data puts the spotlight on RSV vaccines under development Adds details on Moderna vaccine Jan 18 (Reuters) - Moderna Inc MRNA.O said on Tuesday its respiratory syncytial virus (RSV) vaccine was highly effective in preventing at least two symptoms of infections in older adults in a late-stage trial, as drugmakers race to develop a shot against the virus.
A
G
P
S
S

Moderna says RSV vaccine 84% effective at preventing symptoms in older adults

FACTBOX-Moderna data puts the spotlight on RSV vaccines under development Adds details on Moderna vaccine Jan 18 (Reuters) - Moderna Inc MRNA.O said on Tuesday its respiratory syncytial virus (RSV) vaccine was highly effective in preventing at least two symptoms of infections in older adults in a late-stage trial, as drugmakers race to develop a shot against the virus.
A
G
P
S
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.